Skip to content

Bernard Zinman

Mount Sinai Hospital

3 papers in the Anchorcite directory, published between 2015 and 2019, cited 26,918 times in total.

ORCID profile

Research topics

Frequent co-authors

  • Christoph Wanner · 1 paper
  • John M. Lachin · 1 paper
  • DAVID H. FITCHETT · 1 paper
  • Erich Bluhmki · 1 paper
  • Stefan Hantel · 1 paper
  • Michaela Mattheus · 1 paper
  • Theresa Devins · 1 paper
  • Odd Erik Johansen · 1 paper

Papers

  1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine · 2015 · 12,596 citations

    BACKGROUND: The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known. METHODS: We randomly assigned patients to…

  2. Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine · 2016 · 7,900 citations

    BACKGROUND: The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS: In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular…

  3. Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyNew England Journal of Medicine · 2019 · 6,422 citations

    BACKGROUND: Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal…

Metadata from OpenAlex (CC0).